Itinera

Itinera says:

enough

Enough dithering around.
Enough missed opportunities.
This country deserves better policies,
in a better Europe, with more thoughtful choices.

Itinera supports with insights and inspiration
societal leaders who, like us, 
dare to say “enough”.

Every day.

Read moreAbout Itinera

What keeps us awake

Pharma in Belgium and Europe, quo vadis?

Red pill or blue pill? Business as usual is no longer viable for pharma in Europe. The geopolitical landscape is shifting fast and the choices ahead are real.

On March 2, Itinera brings together ~30 senior leaders from pharma, biotech, academia, patient organisations, EU policy, and Belgian government for a high-level roundtable: Pharma in Belgium and Europe - quo vadis? A candid mapping of the new reality and the strategic choices ahead.

With a keynote by Alicia Garcia-Herrero (Chief Economist Asia-Pacific, Natixis; Senior Fellow, Bruegel) on the evolving US-China-EU dynamics shaping European and Belgian biopharma, followed by strategic perspectives from AstraZeneca and Novartis Belux.

No taboos. Just an open, evidence-based exchange on global shifts, innovation, competitiveness, and Europe's industrial strategy. Because a stronger Europe starts with a stronger industry; and a stronger industry starts with a stronger pharmaceutical cluster.

This event will be organized by Itinera in collaboration with AstraZeneca and Novartis.

Stay tuned for the synthesis report full of insights after the event. 

Read more

Don't miss this

Opinion piece

Europe’s Suez moment

With US president Trump living up to his campaign promise to quickly end the war in Ukraine through what Ukraine and Europe fear would be a Russian peace without their involvement, Europe collectively faces its 21st century Suez moment.

Read more